Targeting interferons in systemic lupus erythematosus: current and future prospects.

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a chronic, potentially life-threatening autoimmune disease with complex etiology.
• Emerging research highlights the role of interferon (IFN) signaling pathways in SLE pathogenesis.
• Targeting these pathways represents a novel therapeutic strategy for SLE management.

Purpose of the Study:

• To review preclinical evidence supporting the inhibition of IFN-α and IFN-γ for SLE treatment.
• To discuss emerging therapeutic agents targeting the interferon pathway in SLE.
• To summarize challenges associated with interferon-targeted therapies for SLE.

Main Methods:

• Review of preclinical data on the efficacy of inhibiting IFN-α and IFN-γ.
• Analysis of clinical development of monoclonal antibodies (Mab) and IFN-α kinoid targeting interferon pathways.
• Evaluation of safety and pharmacokinetic profiles from Phase I and II trials.

Main Results:

• Monoclonal antibodies targeting IFN-γ (AMG 811), IFN-α (sifalimumab, rontalizumab, AGS-009), or its receptor (anifrolumab), and IFN-α kinoid are in clinical development.
• Phase I and II trials indicate acceptable short-term safety, with no increased risk of severe viral infections or reactivation.
• These agents demonstrate favorable pharmacokinetics and inhibit IFN-associated gene overexpression.

Conclusions:

• Inhibition of interferon secretion and downstream effectors shows potential for treating SLE.
• While early trials are promising, Phase III trials are necessary to assess the impact on disease activity.
• Further research is needed to address challenges in utilizing interferon-targeted therapies for SLE.